Loading quotes...
Forecast
The analysts' average price target is 18,99€ (+35,35%). The median is 17,59€ (+25,37%).
| Buy |
10 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » More on finance.yahoo.com
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0.00 | - |
| Gross profit | 0.00 | - |
| Net profit | −29.88m | 31,30% |
| EBITDA | −29.79m | 31,13% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 191.90m€ |
Number of shares | 13.62m |
52-week high/low | 14,95€ - 4,34€ |
| Dividends | No |
Beta | 1,4 |
P/E ratio | −3,42 |
PEG ratio | −0,04 |
P/B ratio | 5,47 |
P/S ratio | 0,00 |
Company profile
| Name | Immunic |
| CEO | Erik Lundgren |
| Employees | 95 |
Discover assets
Shareholders of Immunic also invest in the following assets
